Organizational impact analysis of fixed therapy usage in the treatment of CLL

Principal Investigators

Lead Investigators: Patrizio Armeni, Francesco Costa

UB/CeRGAS Team: Patrizio Armeni – Francesco Costa – Carla Rognoni

Client: Janssen Cilag (Now J&J Innovative medicines)

Duration: 10 months

Abstract:  

Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia type in Western countries, affecting primarily older populations. Treatment strategies for CLL include progression-based therapies and fixed-duration therapies (fixed therapy), the latter offering a predetermined treatment cycle. Currently, five different fixed therapies are available, of which only two are reimbursed in Italy. These therapies differ in their administration requirements, resource utilization, and potential impact on healthcare processes, such as hospital visits, patient monitoring, and staff training.

The choice of therapy depends on multiple factors, including the patient’s genetic profile, specific clinical conditions, and healthcare system considerations. Fixed therapies, for example, may reduce long-term resource demands but require upfront organizational adaptation.

The goal of this project is to evaluate the organizational impact of using fixed therapies for CLL treatment. This involves assessing their effects on healthcare infrastructure, communication processes, quality monitoring, staff training, and other operational aspects within the healthcare setting. The findings will provide evidence to support informed decision-making regarding the adoption and optimization of these treatment strategies.

Methods

This study employs an organizational impact analysis approach aligned with the HTA Core Model framework, focusing on evaluating the implications of fixed therapies for CLL treatment across various domains. Key areas of analysis include healthcare infrastructure, process workflows, staff training requirements, and resource utilization.

The research involves systematic data collection and analysis to quantify and visually represent the potential organizational changes triggered by adopting fixed therapies. These insights aim to support stakeholders in making evidence-based decisions regarding the integration and management of these therapeutic options.